institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published 4 days ago • loading... • Updated 4 days ago

CRISPR Therapeutics partners with siRNA company, showing that gene editing isn’t the only answer

Summary by Endpoints News

The gene editing company CRISPR Therapeutics struck a deal worth $95 million upfront with China-based biotech Sirius Therapeutics to jointly develop its experimental gene-silencing siRNA drug for blood clotting disorders. The

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

All

Left

Center

Right

CRISPR Therapeutics partners with siRNA company, showing that gene editing isn’t the only answer

The gene editing company CRISPR Therapeutics struck a deal worth $95 million upfront with China-based biotech Sirius Therapeutics to jointly develop its experimental gene-silencing siRNA drug for blood clotting disorders. The

4 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated4 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Endpoints News broke the news in 4 days ago on Tuesday, May 20, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics